← ANALYST RATINGS · TIPRANKS
Adlai Nortye Ltd. Sponsored ADR (ANL): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $30.80, the highest $49.00, the lowest $20.00. The average is +179.2% from the last price of $11.03.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $11.00 → $11.50+4.5% | Sell | +4.3% | Reiterated | 16.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.00 → $11.50+4.5% | Sell | +4.3% | Reiterated | 16.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.00 → $11.50+4.5% | Sell | +4.3% | Reiterated | 16.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $11.00 → $11.50+4.5% | Sell | +4.3% | Reiterated | 16.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.00 → $11.50+4.5% | Sell | +4.3% | Reiterated | 16.10.26on TipRanks 05:06 | — | |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $20.00 | Buy | +81.3% | Reiterated | 15.10.26on TipRanks 11:12 | +10.8%next day −7.7% | ↗ |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $14.00 → $11.50−17.9% | Hold | +4.3% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $31.00 | Buy | +181.1% | Initiated | 10.09.26on TipRanks 06:25 | +3.3%next day −0.1% · 5 days +0.6% | ↗ |
| Dev Prasad★★★★★★★★★★#663 · hits 80% · avg +91.6% | Lucid Capital | $46.00 → $49.00+6.5% | Buy | +344.2% | Initiated | 08.09.26on TipRanks 06:50 | +3.9%next day −4.8% · 5 days −2.2% | ↗ |
| Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% | Oppenheimer | $32.00 | Buy | +190.1% | Reiterated | 27.08.26on TipRanks 08:31 | −5.6%next day −3.3% · 5 days +2.7% | ↗ |
| Boris Peaker★★★★★★★★★★#357 · hits 49% · avg +22.6% | JonesTrading | $22.00 | Buy | +99.5% | Reiterated | 14.08.26on TipRanks 16:35 | +1.2%next day +6.8% · 5 days +7.3% | ↗ |
| Li Watsek★★★★★★★★★★#11877 · hits 39% · avg −9.1% | Cantor Fitzgerald | — | Buy | — | Reiterated | 16.07.26on TipRanks Jul 20 04:55 | +7.3%next day +2.6% · 5 days +18.1% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $23.00 | Buy | +108.5% | Initiated | 20.03.26on TipRanks 06:15 | +2.0%next day −7.3% · 5 days −10.5% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Adlai Nortye Ltd. Sponsored ADR
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 5 | 7 | 8 | 7 |
| Buy | 1 | 1 | 0 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Adlai Nortye Ltd. Sponsored ADR
- CEO: Yang Lu
- Employees: 109
- 77 Robinson Road, #20-01, Robinson 77, Singapore, 068896, SG
- www.adlainortye.com
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Data from the stock’s TipRanks forecast page, read 171 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗